MX367123B - Formulaciones de pruebas de testosterona proliposomal. - Google Patents
Formulaciones de pruebas de testosterona proliposomal.Info
- Publication number
- MX367123B MX367123B MX2014013450A MX2014013450A MX367123B MX 367123 B MX367123 B MX 367123B MX 2014013450 A MX2014013450 A MX 2014013450A MX 2014013450 A MX2014013450 A MX 2014013450A MX 367123 B MX367123 B MX 367123B
- Authority
- MX
- Mexico
- Prior art keywords
- testosterone
- disclosed
- proliposomal
- testosterone formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Oncology (AREA)
Abstract
Se divulgan formulaciones novedosas de testosterona en donde la testosterona se incorpora en un sistema de fosfolípido/colesterol para producir una dispersión proliposomal en polvo. Las dispersiones proliposomales en polvo del inventor se pueden formular con excipientes farmacéuticamente aceptables para formar composiciones farmacéuticas. Las formas de dosificación oral con cubierta entérica se divulgan ya que son métodos para el tratamiento para la terapia de reemplazo de testosterona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644996P | 2012-05-09 | 2012-05-09 | |
PCT/US2013/040325 WO2013170012A2 (en) | 2012-05-09 | 2013-05-09 | Proliposomal testosterone formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014013450A MX2014013450A (es) | 2015-05-11 |
MX367123B true MX367123B (es) | 2019-08-06 |
Family
ID=49551459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014013450A MX367123B (es) | 2012-05-09 | 2013-05-09 | Formulaciones de pruebas de testosterona proliposomal. |
Country Status (32)
Country | Link |
---|---|
US (5) | US8957053B2 (es) |
EP (1) | EP2846781B1 (es) |
JP (3) | JP6055088B2 (es) |
KR (1) | KR20150032939A (es) |
CN (2) | CN108096192A (es) |
AP (1) | AP2014008099A0 (es) |
AR (1) | AR091006A1 (es) |
AU (2) | AU2013259509B2 (es) |
BR (1) | BR112014027942A2 (es) |
CA (1) | CA2872779A1 (es) |
CL (1) | CL2014003034A1 (es) |
CO (1) | CO7240373A2 (es) |
CR (1) | CR20140561A (es) |
DO (1) | DOP2015000026A (es) |
EA (2) | EA201791738A1 (es) |
EC (1) | ECSP14030572A (es) |
GE (1) | GEP201706754B (es) |
HK (3) | HK1210409A1 (es) |
IL (1) | IL235464B (es) |
IN (1) | IN2014DN10383A (es) |
MA (1) | MA37610B1 (es) |
MX (1) | MX367123B (es) |
MY (1) | MY175305A (es) |
NZ (2) | NZ702634A (es) |
PE (1) | PE20150203A1 (es) |
PH (1) | PH12014502498A1 (es) |
SG (2) | SG10201702240TA (es) |
TN (1) | TN2014000467A1 (es) |
TW (2) | TWI614035B (es) |
UA (1) | UA115058C2 (es) |
WO (1) | WO2013170012A2 (es) |
ZA (2) | ZA201408996B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10213440B2 (en) | 2014-08-20 | 2019-02-26 | Professional Compounding Centers Of America (Pcca) | Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor |
KR101682821B1 (ko) | 2015-07-21 | 2016-12-06 | 서울대학교산학협력단 | 프로리포솜 제조방법 |
CR20180388A (es) * | 2016-01-07 | 2018-09-11 | Univ Western Health Sciences | Formulaciones para el tratamiento del cáncer de vejiga |
WO2017120592A1 (en) * | 2016-01-08 | 2017-07-13 | Western University Of Health Sciences | Proliposomal testosterone undecanoate formulations |
KR102574139B1 (ko) | 2016-07-07 | 2023-09-05 | 삼성전자주식회사 | 무선 충전 모드를 변경하는 장치 및 방법 |
JP7096553B2 (ja) * | 2016-11-11 | 2022-07-06 | ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ | 上部尿路上皮癌の治療方法 |
KR20200088394A (ko) | 2017-11-17 | 2020-07-22 | 에보니크 오퍼레이션즈 게엠베하 | 코팅된 경질 셸 캡슐의 제조 방법 |
US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
US20200101085A1 (en) * | 2018-09-28 | 2020-04-02 | Joel Studin | Transpore delivery of drugs and uses thereof |
KR20220008817A (ko) * | 2019-05-15 | 2022-01-21 | 에보닉 오퍼레이션스 게엠베하 | 캡슐 충전 기계를 사용한 (메트)아크릴레이트 공중합체를 기반으로 하는 코팅을 갖는 충전된 경질 쉘 캡슐의 제조 방법 |
BR112021022648A2 (pt) * | 2019-05-15 | 2021-12-28 | Evonik Operations Gmbh | Processo para preparar cápsulas de invólucro duro cheias com revestimentos à base de celulose ou amido com uma máquina de enchimento de cápsulas |
CN114667133A (zh) * | 2019-08-09 | 2022-06-24 | 泰索克斯制药有限责任公司 | 前体脂质体十一酸睾酮制剂 |
CN110747271B (zh) * | 2019-12-02 | 2023-07-18 | 延边大学 | 关于pci术后血管损伤-再狭窄程度的标记物 |
JP6945874B2 (ja) * | 2019-12-24 | 2021-10-06 | 一般財団法人バイオダイナミックス研究所 | 経口投与用医薬組成物 |
CN111840240A (zh) * | 2020-05-29 | 2020-10-30 | 仁和堂药业有限公司 | 一种非那雄胺制剂及其应用 |
CN112121003B (zh) * | 2020-09-29 | 2022-02-01 | 江苏集萃新型药物制剂技术研究所有限公司 | 缓释制剂载药材料及其组合物、缓释制剂及其制备方法 |
WO2022245650A1 (en) * | 2021-05-19 | 2022-11-24 | Alberto Paz | Orally administered compositions for cancer treatment |
CN114668719B (zh) * | 2022-02-21 | 2023-06-16 | 广东食品药品职业学院 | 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法 |
WO2024056062A1 (zh) * | 2022-09-16 | 2024-03-21 | 长春金赛药业有限责任公司 | 一种甾体类激素磷脂组合物及其制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
US5002936A (en) | 1985-04-12 | 1991-03-26 | Seymour Lieberman | Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds |
US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
DE68914929T2 (de) | 1988-09-29 | 1994-08-11 | Shiseido Co Ltd | Emulgierte Zusammensetzung. |
IE904098A1 (en) | 1989-11-13 | 1991-05-22 | Nova Pharm Corp | Lipospheres for controlled delivery of substances |
US20040175417A1 (en) | 1990-10-19 | 2004-09-09 | Gilead Sciences, Inc. | Amphotericin B liposome preparation |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
JP3017906B2 (ja) | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
US6214375B1 (en) | 1996-07-16 | 2001-04-10 | Generex Pharmaceuticals, Inc. | Phospholipid formulations |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6761901B1 (en) * | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
WO2002051426A2 (en) | 2000-12-22 | 2002-07-04 | A Glenn Braswell | COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTIONS, IMPROVING SEXUAL ACTIVITY AND INCREASING TESTOSTERONE LEVELS, AND IMPROVING MUSCLE STRENGTH AND MASS |
US6534080B2 (en) | 2001-02-12 | 2003-03-18 | Super Gen, Inc. | Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin |
US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
US8658202B2 (en) * | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
US20040115226A1 (en) | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
EP1624857A2 (de) | 2003-05-12 | 2006-02-15 | Novosom AG | Injizierbare depots aus liposomalen aggregaten zur wirkstoffverabreichung |
ES2366646T3 (es) | 2003-11-05 | 2011-10-24 | Elan Pharma International Limited | Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial. |
US20060051406A1 (en) | 2004-07-23 | 2006-03-09 | Manjeet Parmar | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
WO2006062506A1 (en) | 2004-12-03 | 2006-06-15 | Enzrel, Inc. | Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds |
JP2009518443A (ja) | 2005-12-06 | 2009-05-07 | リゲル ファーマシューティカルズ インコーポレーティッド | 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤 |
US20070154403A1 (en) | 2006-01-05 | 2007-07-05 | Thomas Skold | Oral, Pulmonary and Transmucosal Delivery Composition |
US7875289B2 (en) | 2006-03-30 | 2011-01-25 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
AU2008227852B2 (en) * | 2007-03-19 | 2011-02-24 | Fresenius Kabi Oncology Ltd. | Proliposomal and liposomal compositions |
US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
EP2632437A4 (en) * | 2010-10-29 | 2014-03-19 | Univ Western Health Sciences | TERNARY MIX FORMULATIONS |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US20130045271A1 (en) | 2011-08-18 | 2013-02-21 | Monosol Rx, Llc | Steroid hormone delivery systems and methods of preparing the same |
-
2013
- 2013-05-09 KR KR1020147034548A patent/KR20150032939A/ko not_active Application Discontinuation
- 2013-05-09 GE GEAP201313659A patent/GEP201706754B/en unknown
- 2013-05-09 EA EA201791738A patent/EA201791738A1/ru unknown
- 2013-05-09 AP AP2014008099A patent/AP2014008099A0/xx unknown
- 2013-05-09 MX MX2014013450A patent/MX367123B/es active IP Right Grant
- 2013-05-09 EP EP13787438.4A patent/EP2846781B1/en active Active
- 2013-05-09 BR BR112014027942A patent/BR112014027942A2/pt active Search and Examination
- 2013-05-09 NZ NZ702634A patent/NZ702634A/en not_active IP Right Cessation
- 2013-05-09 CN CN201810024730.3A patent/CN108096192A/zh active Pending
- 2013-05-09 MA MA37610A patent/MA37610B1/fr unknown
- 2013-05-09 SG SG10201702240TA patent/SG10201702240TA/en unknown
- 2013-05-09 AU AU2013259509A patent/AU2013259509B2/en not_active Ceased
- 2013-05-09 PE PE2014002002A patent/PE20150203A1/es active IP Right Grant
- 2013-05-09 CN CN201380032890.8A patent/CN104780914B/zh not_active Expired - Fee Related
- 2013-05-09 EA EA201492047A patent/EA028809B1/ru not_active IP Right Cessation
- 2013-05-09 SG SG11201407349UA patent/SG11201407349UA/en unknown
- 2013-05-09 TW TW102116691A patent/TWI614035B/zh not_active IP Right Cessation
- 2013-05-09 MY MYPI2014703308A patent/MY175305A/en unknown
- 2013-05-09 TW TW106138648A patent/TWI664982B/zh not_active IP Right Cessation
- 2013-05-09 IN IN10383DEN2014 patent/IN2014DN10383A/en unknown
- 2013-05-09 AR ARP130101616A patent/AR091006A1/es unknown
- 2013-05-09 JP JP2015511696A patent/JP6055088B2/ja not_active Expired - Fee Related
- 2013-05-09 CA CA2872779A patent/CA2872779A1/en not_active Abandoned
- 2013-05-09 NZ NZ721900A patent/NZ721900A/en not_active IP Right Cessation
- 2013-05-09 WO PCT/US2013/040325 patent/WO2013170012A2/en active Application Filing
- 2013-09-05 UA UAA201413186A patent/UA115058C2/uk unknown
-
2014
- 2014-01-07 US US14/149,227 patent/US8957053B2/en not_active Expired - Fee Related
- 2014-11-02 IL IL235464A patent/IL235464B/en active IP Right Grant
- 2014-11-04 TN TN2014000467A patent/TN2014000467A1/fr unknown
- 2014-11-07 CL CL2014003034A patent/CL2014003034A1/es unknown
- 2014-11-07 PH PH12014502498A patent/PH12014502498A1/en unknown
- 2014-12-04 CR CR20140561A patent/CR20140561A/es unknown
- 2014-12-08 ZA ZA2014/08996A patent/ZA201408996B/en unknown
- 2014-12-09 CO CO14270756A patent/CO7240373A2/es unknown
- 2014-12-09 EC ECIEPI201430572A patent/ECSP14030572A/es unknown
-
2015
- 2015-01-26 US US14/604,985 patent/US9445995B2/en active Active
- 2015-02-12 DO DO2015000026A patent/DOP2015000026A/es unknown
- 2015-09-17 HK HK15109133.2A patent/HK1210409A1/xx unknown
- 2015-12-21 HK HK15112557.3A patent/HK1211499A1/xx not_active IP Right Cessation
- 2015-12-22 ZA ZA2015/09340A patent/ZA201509340B/en unknown
-
2016
- 2016-08-29 US US15/250,169 patent/US9623033B2/en not_active Expired - Fee Related
- 2016-09-19 US US15/268,917 patent/US9844557B2/en not_active Expired - Fee Related
- 2016-12-01 JP JP2016234097A patent/JP6208842B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-07 JP JP2017172142A patent/JP6368020B2/ja not_active Expired - Fee Related
- 2017-11-29 US US15/825,530 patent/US20180303850A1/en not_active Abandoned
- 2017-12-07 AU AU2017272249A patent/AU2017272249B2/en not_active Ceased
-
2018
- 2018-11-23 HK HK18114995.6A patent/HK1255929A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014502498A1 (en) | Proliposomal testosterone formulations | |
IN2014MN00987A (es) | ||
IN2014MN00948A (es) | ||
PH12015501404A1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
IN2014MN00988A (es) | ||
IN2014MN02049A (es) | ||
MX2013011655A (es) | Forma de dosis unitaria para administracion oral. | |
IN2014MN00986A (es) | ||
IN2014MN02598A (es) | ||
IN2012MN02591A (es) | ||
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
PH12016500043A1 (en) | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation | |
IN2014DN06869A (es) | ||
PH12014502065A1 (en) | Vesicular formulations | |
IN2014DN03010A (es) | ||
JO3810B1 (ar) | صيغ التستوستيرون الشحمية المساندة | |
IN2014MN02133A (es) | ||
MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. | |
AU2012902296A0 (en) | Compositions for Therapy and Methods of Treatment | |
GR1007907B (el) | Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |